Study: Thiazolidinediones curb cancer risk in diabetes

04/26/2012 |

Data on 606,583 adult type 2 diabetes patients without a history of cancer revealed those who received thiazolidinediones were less likely to develop liver and colorectal cancers than their counterparts who did not take the drugs. Higher cumulative dosages and longer treatment duration were associated with stronger cancer protection in patients who were on the medications, researchers reported in Hepatology.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX